Background {#Sec1}
==========

HPV is linked to development of cervical, anogenital, head/neck, and lung squamous lesions and carcinomas \[[@CR1]--[@CR5]\]. Increased p16^INK4A^ expression is seen in HPV-associated squamous lesions, and the strength and subcellular staining pattern of p16 immunohistochemical reactivity correlates closely with the degree of dysplasia, with higher-grade lesions showing intense, diffusely positive nuclear and cytoplasmic p16 expression in affected squamous cells \[[@CR6]--[@CR14]\]. Increased p16^INK4A^ expression arises from neutralization of cellular p53 and pRb tumor suppressor proteins by HPV E6 and E7 oncogenes in infected cells \[[@CR15], [@CR16]\]. Low-risk HPV subtypes typically show less p16^INK4A^ induction because they produce E6 and E7 viral oncogenes with lower ability to neutralize endogenous tumor suppressors \[[@CR17]\]. Therefore, p16^INK4A^ expression is commonly employed as a surrogate marker of infection by high-risk HPV subtypes.

Malignant squamous lesions of ocular and peri-ocular structures include conjunctival intraepithelial neoplasia (CIN) to frank invasive squamous cell carcinoma (SCC). HPV has also been detected in prior studies of ocular and peri-ocular squamous lesions and suggested to contribute to the pathogenesis of squamous lesions in the eye \[[@CR18]--[@CR21]\]. However, very few studies have examined p16 expression in squamous lesions resected from the eye, and there have been conflicting findings from these reports. In a cohort of HIV seropositive patients in Africa, Mwololo and colleagues findings found strong p16 immunoreactivity in 67 % (39 of 58) of SCC conjunctival biopsies \[[@CR22]\]. However, in a study of ocular surface and conjunctival squamous lesions performed in Australia, Woods and colleagues found p16 immunoreactivity in only 6.5 % (3 of 46) ocular surface squamous neoplasia biopsies and 12.5 % (3 of 24) conjunctival SCCs \[[@CR23]\]. Interestingly, p16 immunoreactivity completely correlated with HPV detection by PCR in this study \[[@CR23]\].

In our study, we hypothesized that p16 immunoreactivity was significantly increased in malignant ocular squamous lesions. To examine this, we examined 29 ocular surface and periorbital squamous lesions excised at our institution that comprised malignant (CIN and SCC) ocular squamous neoplasms. We performed p16 IHC analysis on all lesions, followed by HPV ISH on a subset of p16-positive cases. We compared the histopathologic and molecular findings with clinical data to identify potential significant correlations between p16 expression in ocular squamous lesions and clinical characteristics of our patient population.

Methods {#Sec2}
=======

Tissue specimens {#Sec3}
----------------

We examined a total of 29 ocular surface and periorbital eyelid squamous lesion cases retrieved from the VA San Diego and UCSD Medical Center between July 2010-May 2014. These cases were routinely fixed in 10 % formalin and embedded in paraffin. H&E (hematoxylin and eosin)-stained slides were reviewed and classified by an ophthalmologic pathologist. All lesions with a diagnosis of CIN or SCC (in situ or invasive) were included in this study. The study was approved by the Institutional Review Boards at UCSD and VA San Diego.

p16 immunohistochemistry {#Sec4}
------------------------

Immunohistochemical studies for p16 were performed using a Ventana Benchmark Ultra. The p16 antibody used was a monoclonal mouse antibody (clone JC8, Santa Cruz Biotechnology; dilution 1:80). Lesions were considered positive for p16 when both cytoplasmic and nuclear staining was observed in epithelial cells. Staining in dendritic cells and non-epithelial cells was disregarded.

HPV *in-situ* hybridization {#Sec5}
---------------------------

*In-situ* hybridization was performed on formalin-fixed, paraffin-embedded tissue by ARUP laboratories (Salt Lake City, Utah). The test was run on a Ventana Bentana Benchmark Ultra (Ventana Medical Systems, Inc), using the INFORM HPV II FAMILY 6 (ASR) probe. A probe set for high-risk HPV \[[@CR16], [@CR18]\] were employed (catalog \#2002899). This test is CLIA-certified for clinical use and widely performed for evaluation of high risk HPVs in suspicious tissue biopsies.

Statistical analysis {#Sec6}
--------------------

Statistical analysis was performed on CINs and SCCs. The correlation between p16 immunoreactivity and patient's age, gender, diagnosis, and ethnicity was first analyzed by Multivariate Logistic Regression using SAS 9.3, followed by individual student's T-test (for age difference) or Fisher's exact test (for gender, ethnicity, or diagnosis differences). A difference was considered statistical significant if p \< 0.05.

Results {#Sec7}
=======

p16 expression by immunohistochemistry {#Sec8}
--------------------------------------

A total of 29 cases were evaluated for p16 immunoreactivity (Table [1](#Tab1){ref-type="table"}). Patients ranged in age from 37 to 88 and included 11 women and 18 men with White ethnicity (by self-report) being the most common. The majority of patients were seronegative for HIV (27/29). Negative p16 immunoreactivity was defined as lacking cytoplasmic and nuclear labeling of the squamous keratinocytes (Fig. [1](#Fig1){ref-type="fig"}), while p16 was considered positive when there was both strong cytoplasmic and nuclear labeling of dysplastic keratinocytes in the lesion. By this criteria, 28 of the 29 cases showed strong p16 immunoreactivity of dysplastic squamous cells (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, and [4](#Fig4){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). When grouped by diagnosis, all of the SCCs (20/20) were p16-positive (Figs. [2](#Fig2){ref-type="fig"} and [4](#Fig4){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}), and 8/9 CINs were p16-positive (Table [1](#Tab1){ref-type="table"}).Table 1Patient clinico-pathologic profilesAgeSexAnatomic siteEthnicityHIV statusPathologic diagnosisP16 immunoreactivityP16 IHC staining patternISH71MEyelidUnknownNegativeInvasive SCCPositiveNuc and cyto^a^85MEyelidWhiteNegativeInvasive SCCPositiveNuc and cyto^a^59MEyelidWhiteNegativeSCC in situPositiveNuc and cyto^a^46MConjunctivaWhiteNegativeinvasive SCCPositiveNuc and cyto^a^78FEyelidWhiteNegativeSCC in situPositiveNuc and cyto^a^37MConjunctivaHispanicNegativeSCC in situPositiveNuc and cytoNegative88FEyelidWhiteNegativeSCC in situPositiveDiffuse nuc and cytoNegative89FEyelidWhiteNegativeSCC in situPositiveDiffuse nuc and cyto^a^67FEyelidWhiteNegativeInvasive SCCPositiveDiffuse nuc and cyto^a^77MConjunctivaWhitePositiveCINPositiveDiffuse nuc and cyto^a^76FEyelidWhiteNegativeSCC in situPositiveDiffuse nuc and cytoNegative47MCorneaWhiteNegativeSCC in situPositiveDiffuse nuc and cyto^a^45FEyelidWhiteNegativeInvasive SCCPositiveDiffuse nuc and cytoNegative76FEyelidWhiteNegativeSCC in situPositiveScattered nuc and cyto^a^61MEyelidWhiteNegativeInvasive SCCPositiveFocal nuc and cytoNegative88FEyelidWhiteNegativeInvasive SCCPositiveDiffuse nuc and cytoNegative88FEyelidWhiteNegativeSCC in situPositivePatchy nuc and cyto^a^88FEyelidWhiteNegativeSCC in situPositiveFocal nuc and cyto^a^45MEyelidWhiteNegativeSCC in situPositiveDiffuse nuc and cyto^a^65MEyelidUnknownNegativeSCC in situPositiveDiffuse nuc and cyto^a^76MConjunctivaHispanicNegativeCINPositiveFocal nuc and cyto^a^32FConjunctivaWhiteNegativeCINPositiveScattered nuc and cyto^a^56MConjunctivaHispanicPositiveCINPositiveScattered nuc and cyto^a^46MCorneaWhiteNegativeCINPositiveDiffuse nuc and cyto^a^64MCornea/conjunctivaUnknownNegativeSCC in situPositiveDiffuse nuc and cyto^a^72MConjunctivaWhiteNegativeCINPositiveDiffuse nuc and cyto^a^56MConjunctivaWhiteNegativeCINPositiveScattered nuc and cyto^a^40MConjunctivaHispanicPositiveCINNegativeN/A^a^70MConjunctivaWhiteNegativeCINPositiveDiffuse nuc and cyto^a^*Nuc* Nuclear, *Cyto* cytoplasmic^a^Not performedFig. 1**a** Histology of the negative control, taken from a pterygia (20x, magnification). **c** Immunohistochemical staining for p16 in the same case (20x magnification). Note the lack of staining in epithelial cells. **b**, **d** Positive control p16 immunohistochemical staining, taken from a squamous cell carcinoma in-situ from cervix (4x and 20x, respectively). Note both cytoplasmic and nuclear reactivityFig. 2**a**, **b** Histology of a squamous cell carcinoma in situ from eyelid biopsy (4x and 20x, respectively). **c**, **d** Immunohistochemical staining for p16 in the same case (4x and 20x, respectively). Note the extensive cytoplasmic and nuclear reactivityFig. 3**a**, **b** Histology of an in-situ squamous cell carcinoma of the conjunctiva from a patient with HIV (4x and 20x, respectively). **c**, **d** Immunohistochemical staining for p16 in the same case (4x and 20x, respectively). Note the lack of p16 staining in adjacent normal conjunctiva with goblet cells. Arrows mark the transition between normal and dysplastic epithelium. **e**, **f** Immunohistochemical staining for Ki-67 (MIB-1). Note full-thickness reactivity in dysplastic epitheliumFig. 4**a**, **b** Histology of an invasive squamous cell carcinoma (4x and 20x, respectively). **c**, **d** Immunohistochemical staining for p16 in the same case (4x and 20x, respectively). Note both cytoplasmic and nuclear reactivity

HPV detection by *in-situ* hybridization {#Sec9}
----------------------------------------

HPV *in-situ* hybridization against HPV genotypes 6, 11, 16, and 18 was performed on 6 lesions in total that were intensely and diffusely positive for p16 by immunohistochemistry. Of six squamous cell carcinomas tested, none were positive for HPV. CIN cases had insufficient remaining tissue in the blocks to perform the HPV ISH assay due to the small size of the conjunctival biopsy.

Clinical and statistical correlation {#Sec10}
------------------------------------

We next examined if positive p16 expression correlated with pathologic type of squamous lesion, patient age (less than or older than 50), patient gender, and ethnicity (White, Hispanic) by multivariate logistic regression, Student's t-test, and Fischer's exact test. No significant differences were seen between the pathologic types of lesions tested and p16 positivity (p \>0.05). In addition, there were no significant differences between p16 positivity and age, gender, ethnicity or diagnosis.

Discussion {#Sec11}
==========

Our study reveals a surprisingly high prevalence of p16 immunoreactivity in ocular squamous lesions from our patient population, but interestingly, these squamous lesions with strong p16 expression did not show HPV 6, 11, 16, and 18 genetic material by ISH. We discuss some potential causes for the increased p16 expression but low HPV infection observed in our study.

P16 immunoreactivity is well established as a biomarker for HPV infection in sites such as cervix, and the vast majority of HPV-associated cancers show increased p16 expression \[[@CR12]--[@CR14], [@CR24], [@CR25]\]. However, p16 induction has also been observed after inflammatory conditions, after total body irradiation, and with prolonged genomic damage, independent of HPV infection \[[@CR26], [@CR27]\] and in a recent study of bladder SCC, about 1/3 of SCC cases showed p16 immunoreactivity but no HPV genetic material by in situ hybridization \[[@CR28]\]. Similarly, increased p16 expression did not correlate with HPV infection in SCC from lung, skin and esophagus \[[@CR29]\]. In our ocular squamous neoplasms, it is possible that increased p16 expression could arise from stresses other than HPV infection, and indeed, solar damage was previously proposed as a risk factor for increased HPV infection in eye disease \[[@CR19]\].

Our HPV ISH test was performed by ARUP labs, using a commercially available limited HPV ISH probe against HPV genotypes 6, 11, 16, and 18 that is widely used to identify HPV infection in human tissue specimens. These HPV genotypes are widely observed in cervical squamous lesions but their trophism to other squamous sites is less clear. Ateenyi-Agaba and colleagues isolated several uncharacterized HPV genotypes from their conjunctival SCC lesions \[[@CR21]\]. It remains possible that in our specimens, other HPV genotypes could be present and account for the increased p16 expression. A broader spectrum probe for more HPV genotypes could help reconcile p16 positive lesions that were initially negative \[[@CR29]\].

HPV detection techniques vary in their sensitivity \[[@CR30]\]. Our study employed a CLIA-approved ISH assay commonly used for cervical biopsies at our institution as a confirmatory test for HPV in p16 positive ocular squamous lesions. RT-PCR testing is more sensitive for HPV testing \[[@CR31], [@CR32]\], and, in one study of oropharyngeal SCCs, many ISH negative SCCs of the oropharynx were positive by PCR \[[@CR33]\]. Repeat HPV testing by different methodologies may be required to identify HPV in cases with high clinical suspicion. Further follow-up studies using more sensitive and broader methodologies may be helpful to determine if p16 expression in ocular squamous lesions corresponds to HPV infection.

Conclusion {#Sec12}
==========

Our studies showed that p16 expression is frequently increased in malignant squamous lesions arising at the conjunctiva or adjoining eyelid.
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